05:08 AM EDT, 09/16/2024 (MT Newswires) -- Genmab ( GMAB ) said Sunday new data from an ongoing phase 1/2 study of rinatabart sesutecan, or Rina-S, showed an "encouraging response rate" in heavily pretreated patients with ovarian cancer.

The data is from the dose expansion part of the study, which is evaluating Rina-S in ovarian cancer and endometrial cancer. The investigational drug showed a confirmed objective response rate of 50% in ovarian cancer patients, Genmab ( GMAB ) said.

The company will further evaluate Rina-S in advanced ovarian cancer in a phase 3 trial expected to start this year, it said.

Price: 26.80, Change: -0.10, Percent Change: -0.37